Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
about
A step forward for patients with NRAS-mutant melanomaCritical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells.Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions.The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models
P2860
Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Optimising the combination dos ...... ed melanoma xenograft tumours.
@en
type
label
Optimising the combination dos ...... ed melanoma xenograft tumours.
@en
prefLabel
Optimising the combination dos ...... ed melanoma xenograft tumours.
@en
P2093
P2860
P356
P1476
Optimising the combination dos ...... ted melanoma xenograft tumours
@en
P2093
Daisy Hartman
Damien M Cronier
Palaniappan Kulanthaivel
Richard P Beckmann
Teresa F Burke
P2860
P2888
P304
P356
10.1038/BJC.2016.40
P407
P50
P577
2016-03-01T00:00:00Z
P5875
P6179
1045191723